Vertex Pharmaceuticals (VRTX) Total Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $7.1 billion for Q1 2026.

• In Q1 2026, Total Liabilities rose 11.56% year-over-year to $7.1 billion; the TTM figure through Mar 2026 stood at $7.1 billion (up 11.56% YoY), while the FY2025 annual figure was $7.0 billion, up 13.94% from the prior year.
• Total Liabilities for Q1 2026 stood at $7.1 billion, up from $7.0 billion in the prior quarter.
• The five-year high for Total Liabilities was $7.5 billion in Q3 2025, with the low at $3.3 billion in Q1 2022.
• The 5-year median for Total Liabilities is $5.4 billion (2024), against an average of $5.5 billion.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities rose 6.84% in 2022, then jumped 41.79% in 2023.
• Vertex Pharmaceuticals' Total Liabilities stood at $4.2 billion in 2022, then rose by 21.51% to $5.1 billion in 2023, then gained by 18.91% to $6.1 billion in 2024, then gained by 13.94% to $7.0 billion in 2025, then grew by 2.08% to $7.1 billion in 2026.
• Business Quant data shows VRTX's Total Liabilities at $7.1 billion in Q1 2026, $7.0 billion in Q4 2025, and $7.5 billion in Q3 2025.